IllnessMedikamenten-Verstoffwechslung, CYP3A4
Summary
Curated single gene sequence analysis according to the clinical suspicion disturbed medication metabolism
- (Extended panel: incl. additional genes)
- EDTA-anticoagulated blood (3-5 ml)
NGS *
Sanger
Gene panel
Selected genes
Name | Exon Length (bp) | OMIM-G | Referenz-Seq. | Heredity |
---|---|---|---|---|
CYP3A4 | 1512 | NM_017460.6 | AD |
Informations about the disease
Although metabolism typically inactivates drugs, some drug metabolites are pharmacologically active—sometimes even more so than the parent compound. An inactive or weakly active substance that has an active metabolite is called a prodrug, especially if designed to deliver the active moiety more effectively. Drugs can be metabolized by oxidation, reduction, hydrolysis, hydration, conjugation, condensation, or isomerization. The enzymes involved in metabolism are present in many tissues but generally are more concentrated in the liver. Drug metabolism rates vary among patients. Some patients metabolize a drug so rapidly that therapeutically effective blood and tissue concentrations are not reached; in others, metabolism may be so slow that usual doses have toxic effects. Individual drug metabolism rates are influenced by genetic factors, coexisting disorders (particularly chronic liver disorders and advanced heart failure), and drug interactions (especially those involving induction or inhibition of metabolism).
- Alias: Cytochrome P450PCN1 (CYP3A4)
- Alias: Glukocorticoid-induceable P450; P450C3
- Alias: Nifedipine oxidase (CYP3A4)
- Oxidative metabolism of many xenobiotics, including ~60% of all clinically used drugs (CYP3A4)
- AD
Bioinformatics and clinical interpretation
No text defined